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Introduction
Cardiovascular (CV) disease (CVD), including ischemic heart disease and stroke, is the leading cause of death worldwide, accounting for 30% of all deaths [1] . Lowdose aspirin is effective in the prevention of ischemic CVs, owing to its antiplatelet properties [2] . There is good evidence that low-dose aspirin also protects against colorectal cancer (CRC) [3] [4] [5] [6] -the third most commonly diagnosed cancer worldwide [7] -and possibly other cancers of the digestive tract, prostate cancer, and breast cancer [8] .
The risk of major bleeding is a well-established adverse effect of low-dose aspirin; however, the availability of gastroprotective agents, such as proton pump inhibitors, to minimize aspirin-associated gastrointestinal (GI) problems, contributes to low-dose aspirin having an acceptable GI safety profile in the general population. Intracranial bleeds (ICBs), although rarer than GI bleeds, are potentially life-threatening events that have also been associated with the use of low-dose aspirin, and that need to be incorporated into risk-benefit assessments. To make clinically meaningful risk-benefit assessments of any drug therapy, it is important to take into account not only the relative risks and benefits of the therapy, but also the frequency of associated events in the target population. Furthermore, it is imperative to obtain estimates of absolute risk that are both valid and precise.
Guidelines recommend long-term use of low-dose aspirin in the setting of secondary CVD prevention [9, 10] , but some uncertainty remains regarding the overall benefit-risk when it is used for primary CVD prevention [9, 11, 12] . Furthermore, there is increasing interest in the balance of overall benefits and risks of low-dose aspirin as a preventive agent, for both CVD and CRC prevention. We aimed to investigate the ICB incidence among new users of low-dose aspirin in UK general practice. The objectives were to obtain incidence rates for all ICB cases and separately for each bleeding type (i.e. intracerebral hemorrhage [ICH] , subdural hematoma [SDH] , or subarachnoid hemorrhage [SAH] ), both overall and stratified by gender, age group, and low-dose aspirin indication (primary or secondary CVD prevention). The study protocol was approved by an independent scientific review committee for The Health Improvement Network (THIN) (reference number 14-088A1).
Methods

Data source
We used data from THIN, a population-based primarycare database of anonymized patient medical records in the UK. Almost all of the UK population are registered with a primary-care practitioner (PCP), and THIN currently covers 6% of the UK population [13] . The database is representative of the UK population with regards to age, gender, and geographic distribution, and has been validated for use in pharmacoepidemiologic research [14, 15] . Almost 600 general practices throughout the UK have contributed data to THIN [13] . Participating PCPs record data prospectively as part of their routine patient care, and send their data anonymously to THIN for use in research projects. Patient information is entered by the use of Read codes or as free text. Read codes are the standard clinical terminology used in UK general practice, supporting detailed clinical encoding of diagnoses, symptoms, laboratory tests and results, therapeutics, surgical procedures, and demographics [16] . Prescriptions are entered by the use of Gemscript codes based on the National Health Service (NHS) dictionary of medicines and devices [17] , and are automatically recorded upon issue. Information from secondary care is communicated back to the PCP and entered in the database retrospectively. For a subset of THIN practices, data can be linked at the patient level to Hospital Episode Statistics (HES) (20% at the time of the study) [18] . HES contain clinical and administrative data on hospital episodes (admissions and visits), which are collected from UK NHS hospitals and linked to International Classification of Diseases (ICD)-10 codes.
Identification and follow-up of the study cohort
The study design is illustrated in Fig. 1 . The source population comprised individuals in THIN aged 40-84 years between 1 January 2000 and 31 December 2012 who met the following inclusion criteria before being eligible to enter the study: at least 2 years of registration with the PCP, at least 1 year since the beginning of their computerized prescription history, and at least one encounter/visit recorded in the previous 3 years (N = 2 354 840). Individuals were excluded if they had a prescription for low-dose aspirin (75 mg or 300 mg; tablets available in the UK) or a diagnosis of cancer, alcohol abuse, coagulopathies, esophageal varices or chronic liver disease at any time before study entry. Individuals aged ≥ 70 years with a follow-up of > 1 year and with fewer than two recorded consultations with a PCP during their entire follow-up (a proxy for incomplete and/or invalid data recording) were also excluded. After application of these exclusion criteria, the THIN source population comprised a total of 1 840 253 individuals (78% of the original source population).
Within the source population, we identified a cohort of new users of low-dose aspirin (N = 199 079), with the date of first low-dose aspirin prescription being set as the start of follow-up (start date). The cohort was followed for up to 14 years until the earliest of the following: a Read code for ICBs, cancer, alcohol abuse, coagulopathies, esophageal varices, chronic liver disease, age of 90 years, death, or the end of the study period (31 December 2013). Individuals with a Read code for ICBs during follow-up (N = 1204) were identified as potential incident ICB cases.
Validation of ICB cases
To validate the recorded ICB diagnosis, we undertook a three-step process (Fig. 2) . First, we identified individuals who had been confirmed as either an incident ICB case (n = 215) or a non-case (n = 105) during previous research projects in THIN [19, 20] . Second, among the remaining individuals who could not be cross-linked to previous projects (n = 884), we identified those belonging to general practices linked to HES (n = 305), and performed automated computer searches among these individuals' HES records for ICD-10 codes suggestive of ICBs, with subsequent manual review of HES records to confirm the diagnosis. Following this process, 122 potential cases were confirmed as incident cases, 12 were deemed to be non-cases by virtue of meeting the study exclusion criteria, and 171 remained unconfirmed. Third, for all potential cases not cross-linked to previous projects and either not linked to HES (n = 579) or linked to HES but not confirmed by review of HES data (n = 171), we manually reviewed these patients' medical records in THIN (including free-text comments) while masked to all medication exposure. Patients were considered to be incident cases unless there was evidence from their records to indicate otherwise, e.g. a prevalent case or no definite diagnosis. Cases were classified as ICH, SAH, or SDH, and according to whether the event was trauma-related or non-trauma-related. The index date was the date of the recorded ICB diagnosis. Cases who died on the index date or within 30 days following the index date were deemed to be fatal cases.
Covariates
Patient characteristics were ascertained at the start of follow-up. In addition to demographics, we collected information on lifestyle variables (smoking status, alcohol consumption, and body mass index), comorbidities, and healthcare use (number of PCP visits, referrals and hospitalizations). Lifestyle variables and comorbidities were ascertained at any time before the start date, whereas healthcare use was ascertained in the year before the start date, by use of the most recent value/status where appropriate. Medication use was defined as use on the start date or within the previous 90 days. The indication for low-dose aspirin use -primary or secondary CVD prevention -was established for each member of the study cohort by use of an automated computer algorithm, as described previously [21] .
Statistical analysis
The characteristics of the study cohort at the start of follow-up were described by the use of frequency counts and percentages for categorical variables, and means with standard deviation for continuous variables. Incidence rates per 100 person-years with 95% confidence intervals (CIs) were calculated for all ICB cases and for each bleeding location (ICH, SDH, or SAH), and stratified by case-fatality status, trauma-related status, gender, age group, and low-dose aspirin indication. Because of the potential for low-dose aspirin users to discontinue their treatment during follow-up [22] and the greater likelihood of this happening with increasing duration of follow-up, an additional analysis was undertaken to estimate the overall ICB incidence, restricting the study cohort to individuals who did not discontinue low-dose aspirin use throughout their observed follow-up (continuous users).
To identify this subgroup of low-dose aspirin users, we used a conservative approach, whereby continuous users were all individuals who were exposed to low-dose aspirin during their complete follow-up time. Sensitivity analyses were performed, calculating the incidence rates of all ICBs and of each subtype during the first year of followup after removal of warfarin users and separately after removal of clopidogrel users from the study cohort. In a separate analysis, we estimated incidence rates of ICBs and each bleeding subtype among a matched comparison cohort of individuals who were non-users of low-dose aspirin at the start of follow-up (1 : 1 matching by age, gender, time since study entry, and number of PCP visits/ encounters in the year before the start of follow-up).
Results
Characteristics of the study cohort
The baseline characteristics of the study cohort are shown in Table 1 . The mean and median ages at the start of follow-up were 63.9 years and 64.0 years, respectively, and 51.5% were male. Approximately 21% of the cohort were smokers, and 7% were heavy alcohol drinkers (> 21 units weekly). The most prevalent comorbidity was hypertension, affecting almost half of the study cohort; < 1% of the cohort had experienced a previous ICB.
New users of low-dose aspirin cohort (N = 199 079)
Read code for ICB during follow-up (n = 1204)
Step 1. Identified and validated in previous research projects (n = 320)
Step 2. Linked to HES (n = 305)
Step Sixty-three per cent of the study cohort had been prescribed low-dose aspirin for primary prevention of CVD. These individuals were healthier than those prescribed low-dose aspirin for secondary CVD prevention with regard to smoking, high alcohol intake, number of previous PCP visits, and several comorbidities (prior ICB, heart failure, hypercholesterolemia, deep vein thrombosis, and GI disorders). However, diabetes and hypertension were more prevalent among the primary-prevention lowdose aspirin users.
Incidence of ICB
A total of 881 incident ICB cases (n = 407 for ICH, n = 283 for SDH, and n = 191 for SAH) were identified during 1 157 112 years of follow-up (the median followup was 5.58 years). Incidence rates of all ICBs and separately for ICH, SDH and SAH are shown in Table 2 overall and stratified by gender, age group, case-fatality status (fatal/non-fatal), and whether the event was recorded as trauma-related (trauma-related/non-traumarelated). The overall ICB incidence was 0.08 cases per 100 person-years (95% CI 0.07-0.08); corresponding incidence rates for each bleeding subtype were 0.04 (95% CI 0.03-0.04) for ICH, 0.03 (95% CI 0.02-0.03) for SDH, and 0.02 (95% CI 0.01-0.02) for SAH. Incidence rates in the first year of follow-up were similar for all ICB cases and for each bleeding subtype: 0.08 (95% CI 0.07-0.09) for all ICBs, 0.04 (95% CI 0.03-0.05) for ICH, 0.02 (95% CI 0.02-0.03) for SDH, and 0.02 (95% CI 0.02-0.03) for SAH. When we restricted our study cohort to individuals with continuous low-dose aspirin use throughout follow-up (N = 58 551), the overall ICB incidence was 0.13 per 100 person-years (95% CI: 0.11-0.14), which was higher than the rate among the whole study cohort.
In the sensitivity analysis, the ICB incidence per 100 person-years during the first year of follow-up was similar, albeit slightly lower, after removal of warfarin users from the study cohort (0.07, 95% CI 0.06-0.09), and was also similar after removal of clopidogrel users (0.07, 95% CI 0.07-0.09). Corresponding results for each bleeding subtype are shown in Table S1 ). Twenty-one per cent of all ICB cases were fatal (death within 30 days; 185/881); the mean age of fatal cases was 71.6 years (median 74 years), and the mean age of nonfatal cases was 67.6 years (median 69 years). Case-fatality rates by ICB location were 27.3% (111/407) for ICH, 9.9% (28/283) for SDH, and 24.1% (46/191) for SAH. The incidence rates of non-fatal and fatal ICBs were 0.06 (95% CI 0.06-0.06) and 0.02 (95% CI 0.01-0.02) per 100 person-years, respectively. When restricted to the first year of follow-up, incidence rates were the same for nonfatal ICBs (0.06 per 100 person-years, 95% CI 0.05-0.07) and slightly higher for fatal ICBs (0.02 per 100 person-years, 95% CI 0.01-0.03). Trauma-related cases accounted for 28.4% (250/881) of all ICB cases, 11.8% The incidence of trauma-related SDH was 0.01 (95% CI 0.01-0.02), which was, as expected, higher than the incidence of trauma-related ICH (0.004, 95% CI 0.003-0.006) and trauma-related SAH (0.003, 95% CI 0.002-0.004) (Fig. 3) . Incidence rates of all ICBs, ICH, SDH and SAH stratified by both case-fatality status and by trauma-related status are shown in Table S2 ; those for SDH are also shown in Fig. S1 . ICB incidence rates were higher in men than women for SDH, whereas, for ICH and SAH, they were higher in women. For ICH and SDH, incidence rates increased notably with age, whereas for SAH they remained broadly similar, increasing only slightly with age (Fig. 4) . Overall and age-stratified and sex-stratified ICB incidence rates according to the indication for low-dose aspirin (primary or secondary CVD prevention) are shown in Fig. 5 for all ICB cases and for each subtype. Overall, the ICB incidence was higher among members of the cohort who received low-dose aspirin for secondary CVD prevention (0.09 per 100 person-years, 95% CI 0.08-0.01) than among those who received low-dose aspirin for primary CVD prevention (0.07 per 100 person-years, 95% CI 0.06-0.07).
As shown in Table S3 , the ICB incidence was lower among the matched comparison cohort of non-users than among the low-dose aspirin cohort at the start of follow-up, both overall (0.07 per 100 person-years; 95% CI 0.06-0.07) and among each age stratum (Table S4) .
Discussion
In this population-based study, we have estimated the absolute ICB risk in new users of low-dose aspirin in the UK overall and in several patient subgroups. Previous estimates of the ICB incidence in low-dose aspirin users have come from randomized trials [9, 23] , and we are unaware of other estimates available from the general population apart from those of ICBs and GI bleeding combined [24] , or from specific patient populations [25] . Our results therefore provide valuable measures for incorporation into benefit-risk assessments of low-dose aspirin use in CVD prevention and potential CRC prevention. Our study is also novel in that it provides estimates of the ICB incidence among new users of low-dose aspirin according to ICB location, and further stratified by casefatality status and according to whether the event was trauma-related. Intracranial bleeding is a serious adverse event with a high case-fatality rate in the general population -a previous population-based study found the 30-day case-fatality rates to be 42.0% for non-traumatic ICH and 28.7% for non-traumatic SAH, and that more than one-third of patients die in the first month after diagnosis [26] . In comparison, among our cohort of lowdose aspirin users, the 30-day case-fatality rates were lower, at 27% for ICH and 24% for SAH, although, for non-traumatic events (data not shown), the estimates in our study cohort were 29.0% for ICH and 36.8% for SAH.
Strengths of our study include the use of a validated patient medical records database that is representative of the UK population, the long follow-up duration, and the inclusion of a broad range of real-world patients. In addition, the large size of the database meant that we were able to obtain precise estimates of the ICB incidence, and the use of a cohort of 'new users' of low-dose aspirin removed the possibility of survivor bias, which would have been present if prevalent users had been included. The recorded ICB diagnoses were validated through a multistep process, including linkage to hospitalization data and/or through manual review of patient records in THIN. Our study cohort is likely to have captured nearly all new users of low-dose aspirin in our source population who met the study inclusion criteria. Low-dose aspirin is available in the UK over the counter; however, we have found in a previous validation study in THIN that the level of misclassification resulting from under-recorded use of over-the-counter low-dose aspirin is minimal [21] .
Another previous study comparing aspirin prescription records in the Clinical Practice Research Datalink GOLD (a UK database similar to THIN) with patient selfreports found that the majority of chronic aspirin use was captured by prescription records [27] . One limitation of our study is the possibility that members of the study cohort could have discontinued low-dose aspirin use during follow-up. To minimize this possibility, we undertook an additional analysis with restriction of our study cohort to those with continuous use throughout follow-up, and found that the absolute ICB risk was higher among these individuals. The decision to prescribe low-dose aspirin for CVD prevention is dependent on several largely age-dependent factors, including whether the patient has previously experienced, or is at high risk of, experiencing an ischemic CV event, and the risk of major bleeding events. Even taking into account the risk of major bleeding associated with the long-term use of low-dose aspirin, the net clinical benefit is clearly in favor of low-dose aspirin use in the secondary-prevention setting [9] . Although the benefit-risk assessment of the use of low-dose aspirin in the primary-prevention setting has been less certain, recent recommendations from the US Preventive Services Task Force recommend long-term use of low-dose aspirin for primary prevention of CRC and CVD among adults aged 50-59 years who have a ≥ 10% 10-year CVD risk and who are not at increased risk of bleeding, have a lifeexpectancy of at least 10 years, and are willing to take low-dose aspirin for at least 10 years [28] . For comparable adults aged 60-69 years, the Task Force recommends that the decision to take low-dose aspirin for primary CRC and CVD prevention should be made on an individual basis. In a recent meta-analysis using data from 14 randomized controlled clinical trials of low-dose aspirin in the primary-prevention setting, Xie et al. [11] found aspirin to be associated with a 34% increase in ICBs and a 55% increase in major bleeding, but this was offset by a 10% reduction in major CVD events, a 14% reduction in myocardial infarction, and a 14% reduction in ischemic stroke. However, some of the included studies investigated aspirin doses of ≥ 500 mg daily, and the authors did not include trials of CRC in the primary-prevention setting in their overall evaluation. Using the same THIN source population and a similar time period as in this current study, we have previously calculated incidence rates of CRC among new users of low-dose aspirin stratified by age and gender, and according to primary or secondary CVD prevention population (L. A. Garc ıa Rodr ıguez, unpublished). Both these estimates for CRC and the estimates for ICBs obtained in this current study are necessary components for a valid benefit-risk assessment of low-dose aspirin in our patient population.
For a complete benefit-risk evaluation to be made, population-based estimates of the absolute excess risk of ICBs, CVD and GI bleeds are also needed, and we aim to provide these in forthcoming studies. Alongside the quantification of risks and benefits, when risk management decisions about low-dose aspirin are being made, the positive and negative effects on individuals' quality of life should also be considered.
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L. Cea Soriano contributed to the study design, the acquisition, analysis and interpretation of data, review of the manuscript, and decision to submit the manuscript for publication. D. Gaist contributed to the study design, review of ICB cases, interpretation of data, review of the manuscript, and decision to submit the manuscript for publication. M. Soriano-Gabarr o contributed to the study concept, study design, interpretation of data, review of the manuscript, and decision to submit the manuscript for publication. L. A. Garc ıa Rodr ıguez contributed to the study concept, study design, acquisition, analysis and interpretation of data, review of the manuscript, and decision to submit the manuscript for publication. Fig. S1 . Incidence rate of SDH per 100 person-years (with 95% CIs) by trauma/non-trauma-related status and case fatality (death within 30 days following the event). Table S1 . Incidence of ICBs per 10 000 person-years (95% CI) in the first year of follow-up, according to composition of the low-dose aspirin cohort. Table S2 . Incidence rates of all ICBs, ICH, SDH and SAH per 10 000 person-years stratified by case-fatality status (death within 30 days following the event) and trauma-related status. Table S3 . Crude incidence rates of all ICBs, ICH, SDH and SAH per 10 000 person-years (95% CI) among the comparison cohort of non-users of low-dose aspirin at the start of follow-up. Table S4 . Crude incidence rate of ICB per 10 000 personyears (95% CI) among the non-user comparison cohort stratified by age group.
